TASLY(SH:600535)2014-03-28 16:00Financial Performance - The net profit attributable to the parent company for 2013 was CNY 1,100,261,478.36, with a net profit from the parent company's financial statements of CNY 940,106,248.22[6]. - The total revenue for 2013 reached CNY 11,097,870,213.22, representing an 18.80% increase compared to CNY 9,341,788,352.54 in 2012[23]. - The net profit attributable to shareholders of the listed company was CNY 1,100,261,478.36, a 29.41% increase from CNY 850,185,026.03 in the previous year[23]. - The net profit after deducting non-recurring gains and losses was CNY 1,020,384,030.89, reflecting a 37.52% increase compared to CNY 742,001,972.30 in 2012[23]. - Basic earnings per share for 2013 were CNY 1.07, up 29.41% from CNY 0.82 in 2012[24]. - The company's total assets increased by 25.46% to CNY 10,212,206,388.61 from CNY 8,139,854,259.76 in 2012[23]. - The company's market capitalization increased from CNY 28.5 billion at the beginning of the year to CNY 44.3 billion by the end of the reporting period, adding CNY 15.8 billion in value[29]. - The company's total revenue for the period reached CNY 10,994,872,779.21, representing an 18.33% increase compared to the previous period[58]. Dividend Distribution - The proposed cash dividend distribution is CNY 3.5 per 10 shares, totaling CNY 361,494,928.90 for all shareholders[6]. - The undistributed profits after the dividend distribution will amount to CNY 1,686,255,981.25[6]. - The company has maintained a positive retained earnings balance and has not proposed a cash dividend distribution plan for the reporting period[108]. Acquisitions and Investments - The company completed acquisitions of Jiangsu Tianshili Diyi Pharmaceutical Co., Ltd., Tianjin Tianshili Shent Pharmaceutical Co., Ltd., and Henan Tiandi Pharmaceutical Co., Ltd., enhancing its biopharmaceutical industry structure[29]. - The company acquired 100% equity of Jiangsu Tian Shili Di Yi Pharmaceutical Co., Ltd. for CNY 1,450 million, which was approved by the board and shareholders[115]. - The company acquired 45% equity in Henan Tiandi Pharmaceutical Co., Ltd. for RMB 151.02 million, with the payment completed by September 29, 2013[130]. - The company holds a 100% stake in Jiangsu Tianshili Diyi Pharmaceutical Co., Ltd., which specializes in the production of various pharmaceutical forms including tablets and hard capsules[92]. Research and Development - R&D expenditure increased by 72.67% to ¥364,181,113.80, representing 3.28% of the total operating revenue[37][44]. - The company’s investment in research and development has been increasing, establishing a new model for "component traditional Chinese medicine" research[64]. - The company aims to enhance R&D efficiency by establishing an integrated R&D system, focusing on the development of products related to "Dan Shen" and expanding the production line capacity[97]. Risk Management and Compliance - The company has established a comprehensive internal control evaluation system to enhance management and compliance, focusing on risk control and process improvement[177]. - The company has implemented measures to mitigate the risk of product price reductions by focusing on unique products and benefiting from supportive government policies[100]. - The company has established a risk allowance and risk reserve system, allocating 2.6% of annual net profit for this purpose[157]. Market Strategy - The company’s marketing strategy focuses on a "big product, big terminal, big market" approach, emphasizing professional product line development[38]. - The company emphasizes an integrated marketing strategy focusing on domestic markets while targeting international expansion[95]. - The company is enhancing its marketing strategy by building a multi-layered marketing organization and utilizing big data and cloud marketing to optimize market distribution[98]. Corporate Governance - The company has received multiple awards for corporate governance, including the "Board of Directors Award" in 2011 and the "Information Disclosure Award" in 2012[167]. - The company has a transparent information disclosure policy, ensuring timely and accurate communication with investors, particularly minority shareholders[169]. - The company has established a system for managing insider information to prevent insider trading, ensuring the quality of information disclosure[170]. Employee and Management - The total number of employees in the parent company is 7,113, while the total number of employees in major subsidiaries is 1,688, resulting in a combined total of 8,801 employees[161]. - The company has a professional composition of 2,120 production personnel, 5,069 sales personnel, 1,023 technical personnel, 105 financial personnel, and 484 administrative personnel[161]. - The total remuneration for directors, supervisors, and senior management personnel amounts to 17.122 million yuan[157]. Financial Strategy - The company’s financial strategy includes effective risk control while improving fund utilization efficiency[76]. - The company plans to use up to 350 million RMB of temporarily idle funds for low-risk short-term financial products[76]. - The company has engaged in various financial investments, including a total of CNY 1.94 billion in wealth management products[71].